희귀질환 치료 시장 : 약물 유형, 치료 영역, 환자, 투여 경로별 - 예측(2024-2032년)

Global Rare Disease Treatment Market will reach a 9% CAGR from 2024 to 2032, attributed to advancements in medical research coupled with robust biopharmaceutical investments. Breakthroughs in gene therapies, precision medicine, and targeted treatments are reshaping therapeutic approaches. Moreover, increased funding and collaboration within the biopharmaceutical sector are accelerating the development of innovative therapies for rare diseases. These efforts enhance treatment options and address unmet medical needs, fostering a dynamic market environment focused on improving outcomes and quality of life for patients with rare diseases globally.

For instance, in April 2024, LifeArc initiated £40 million in research centers aimed at discovering novel tests, treatments, and cures for individuals affected by rare diseases. By fostering innovation in tests, treatments, and potential cures, LifeArc's initiative has the potential to accelerate breakthroughs, enhance patient outcomes, and expand the market's capacity for effective rare disease therapies on a global scale.

The rare disease treatment industry is classified based on drug type, therapeutic area, patient, route of administration, and region.

The injectable segment will see a notable surge between 2024 and 2032, owing to its efficacy and rapid onset of action. Many rare diseases require precise, targeted delivery of medication, which injectables provide. This method also ensures higher bioavailability compared to oral drugs. The rise in biologics and monoclonal antibodies, commonly administered via injection, further boosts this segment. Additionally, advancements in injection technologies and the growing prevalence of chronic rare diseases contribute to the injectable segment's market dominance.

The blood-related disorder segment will amass remarkable gains through 2032, propelled by the high prevalence of rare hematological conditions like hemophilia, thalassemia, and sickle cell anemia. These disorders often require specialized, long-term treatment and management, driving demand for innovative therapies. Advances in gene therapy, targeted treatments, and increasing research funding contribute to this segment's growth. Additionally, heightened awareness and improved diagnostic capabilities ensure that blood-related disorders remain a significant focus in the rare disease treatment market.

Asia Pacific will secure a substantial market presence from 2024 to 2032, driven by rising healthcare spending, expanding patient populations, and improving healthcare infrastructure. Countries like China, Japan, and India are investing heavily in rare disease research and treatment facilities. Additionally, increasing awareness among healthcare professionals and patients about rare diseases is boosting market growth in the region. Asia Pacific's pivotal contribution to advancements in medical research and innovation will further solidify its role as a key contributor to the rare disease treatment industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increase in the prevalence of rare diseases
    • 3.2.1.2 Favorable government policies
    • 3.2.1.3 Growing number of new drug launches
    • 3.2.1.4 Increasing R&D activities for novel therapeutics drugs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness regarding rare disease treatment
    • 3.2.2.2 High cost of the drugs and therapy
• 3.3 Growth potential analysis
• 3.4 Clinical trial scenario for rare disease treatment
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Technology landscape
• 3.8 Epidemiology scenario
• 3.9 Current therapies
• 3.10 Reimbursement scenario
• 3.11 Regulatory landscape
• 3.12 Porter's analysis
• 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Biologics
• 5.3 Non-biologics

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
• 6.3 Blood-related disorders
• 6.4 Central nervous system
• 6.5 Respiratory disorders
• 6.6 Musculoskeletal disorders
• 6.7 Cardiovascular disorders
• 6.8 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Patient, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Adult
• 7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Poland
  • 9.3.7 Switzerland
  • 9.3.8 Sweden
  • 9.3.9 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Indonesia
  • 9.4.7 Thailand
  • 9.4.8 Vietnam
  • 9.4.9 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Chile
  • 9.5.5 Colombia
  • 9.5.6 Peru
  • 9.5.7 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Israel
  • 9.6.5 Egypt
  • 9.6.6 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Alexion Pharmaceuticals, Inc.
• 10.3 Amgen Inc
• 10.4 AstraZeneca PLC
• 10.5 Baxter International
• 10.6 Bayer AG
• 10.7 Biogen
• 10.8 Bristol-Myers Squibb
• 10.9 Eli Lilly and Company
• 10.10 F. Hoffmann La Roche Ltd
• 10.11 GSK plc
• 10.12 Johnson & Johnson
• 10.13 Merck & Co. Inc.
• 10.14 Novartis AG
• 10.15 Novo Nordisk
• 10.16 Pfizer, Inc.
• 10.17 Pharmacyclics LLC
• 10.18 Sanofi SA
• 10.19 Seagen Inc.
• 10.20 Takeda Pharmaceutical Company Ltd.
• 10.21 Vertex Pharmaceutical Inc.